Lao People's Democratic Republic

Lao People's Democratic Republic

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
8.66 (7.32 - 10) 2019 Modelled IHME
8.7 (7.44 - 10.03) 2018 Modelled IHME
8.79 (7.39 - 10.35) 2017 Modelled IHME
9.07 (7.75 - 10.48) 2016 Modelled IHME
9.42 (8.03 - 10.93) 2015 Modelled IHME
9.64 (8.18 - 11.14) 2014 Modelled IHME
9.82 (8.30 - 11.33) 2013 Modelled IHME
9.98 (8.39 - 11.59) 2012 Modelled IHME
10.15 (8.44 - 11.88) 2011 Modelled IHME
10.33 (8.57 - 12.23) 2010 Modelled IHME
10.56 (8.74 - 12.45) 2009 Modelled IHME
10.82 (8.98 - 12.66) 2008 Modelled IHME
11.08 (9.21 - 12.96) 2007 Modelled IHME
11.3 (9.39 - 13.28) 2006 Modelled IHME
11.44 (9.50 - 13.52) 2005 Modelled IHME
11.51 (9.62 - 13.52) 2004 Modelled IHME
11.57 (9.66 - 13.53) 2003 Modelled IHME
11.61 (9.66 - 13.69) 2002 Modelled IHME
11.66 (9.72 - 13.79) 2001 Modelled IHME
11.72 (9.74 - 13.92) 2000 Modelled IHME
11.81 (9.85 - 14.05) 1999 Modelled IHME
11.93 (9.96 - 14.18) 1998 Modelled IHME
12.05 (10.06 - 14.30) 1997 Modelled IHME
12.15 (10.13 - 14.43) 1996 Modelled IHME
12.18 (10.12 - 14.56) 1995 Modelled IHME
12.17 (10.12 - 14.42) 1994 Modelled IHME
12.11 (10.04 - 14.27) 1993 Modelled IHME
12.02 (9.93 - 14.12) 1992 Modelled IHME
11.9 (9.79 - 13.94) 1991 Modelled IHME
11.74 (9.57 - 13.81) 1990 Modelled IHME
4.81 (3.74 - 5.99) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
2.11 (1.56 - 2.69) 2019 Modelled IHME
2.21 (1.66 - 2.83) 2018 Modelled IHME
2.3 (1.69 - 2.97) 2017 Modelled IHME
2.37 (1.76 - 3.03) 2016 Modelled IHME
2.46 (1.80 - 3.14) 2015 Modelled IHME
2.59 (1.92 - 3.27) 2014 Modelled IHME
2.77 (2.07 - 3.49) 2013 Modelled IHME
2.99 (2.25 - 3.78) 2012 Modelled IHME
3.25 (2.46 - 4.12) 2011 Modelled IHME
3.53 (2.66 - 4.54) 2010 Modelled IHME
3.89 (2.92 - 4.99) 2009 Modelled IHME
4.36 (3.29 - 5.62) 2008 Modelled IHME
4.89 (3.66 - 6.35) 2007 Modelled IHME
5.44 (4.05 - 7.14) 2006 Modelled IHME
5.99 (4.41 - 7.96) 2005 Modelled IHME
6.6 (4.93 - 8.60) 2004 Modelled IHME
7.31 (5.48 - 9.45) 2003 Modelled IHME
8 (5.95 - 10.44) 2002 Modelled IHME
8.56 (6.43 - 11.24) 2001 Modelled IHME
8.88 (6.58 - 11.71) 2000 Modelled IHME
9.03 (6.85 - 11.82) 1999 Modelled IHME
9.17 (6.97 - 11.92) 1998 Modelled IHME
9.27 (7.13 - 11.99) 1997 Modelled IHME
9.34 (7.17 - 11.97) 1996 Modelled IHME
9.36 (7.09 - 12.13) 1995 Modelled IHME
9.35 (7.18 - 12.10) 1994 Modelled IHME
9.32 (7.11 - 12.09) 1993 Modelled IHME
9.26 (6.98 - 12.05) 1992 Modelled IHME
9.17 (6.78 - 12.04) 1991 Modelled IHME
9.05 (6.57 - 12.05) 1990 Modelled IHME
1.94 (1.34 - 2.73) 2015 Modelled WHO
1.7 2012 Survey/reported WHO WPRO, Woodring J et al, 2017
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
42 (33 - 51) 2019 Modelled IHME
42 (33 - 51) 2018 Modelled IHME
42 (33 - 52) 2017 Modelled IHME
43 (34 - 52) 2016 Modelled IHME
43 (34 - 53) 2015 Modelled IHME
43 (35 - 53) 2014 Modelled IHME
43 (35 - 53) 2013 Modelled IHME
44 (35 - 53) 2012 Modelled IHME
44 (35 - 54) 2011 Modelled IHME
44 (35 - 54) 2010 Modelled IHME
44 (36 - 54) 2009 Modelled IHME
45 (36 - 55) 2008 Modelled IHME
45 (36 - 55) 2007 Modelled IHME
45 (36 - 55) 2006 Modelled IHME
45 (36 - 55) 2005 Modelled IHME
45 (36 - 55) 2004 Modelled IHME
45 (36 - 55) 2003 Modelled IHME
45 (36 - 55) 2002 Modelled IHME
45 (36 - 55) 2001 Modelled IHME
44 (35 - 55) 2000 Modelled IHME
44 (35 - 55) 1999 Modelled IHME
44 (35 - 55) 1998 Modelled IHME
44 (35 - 55) 1997 Modelled IHME
44 (35 - 55) 1996 Modelled IHME
44 (35 - 55) 1995 Modelled IHME
44 (35 - 55) 1994 Modelled IHME
44 (35 - 55) 1993 Modelled IHME
44 (35 - 55) 1992 Modelled IHME
44 (35 - 55) 1991 Modelled IHME
44 (35 - 56) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of HepB birth dose

Newborns
Download
Value (%) Year Type Source
55 2018 Survey/reported WHO/UNICEF
55 2017 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
68 2018 Survey/reported WHO/UNICEF
69 2017 Survey/reported WHO/UNICEF
66 2016 Survey/reported WHO/UNICEF
81 2015 Survey/reported WHO/UNICEF
88 2014 Survey/reported WHO/UNICEF
87 2013 Survey/reported WHO/UNICEF
79 2012 Survey/reported WHO/UNICEF
78 2011 Survey/reported WHO/UNICEF
74 2010 Survey/reported WHO/UNICEF
67 2009 Survey/reported WHO/UNICEF
61 2008 Survey/reported WHO/UNICEF
50 2007 Survey/reported WHO/UNICEF
57 2006 Survey/reported WHO/UNICEF
49 2005 Survey/reported WHO/UNICEF
45 2004 Survey/reported WHO/UNICEF
50 2003 Survey/reported WHO/UNICEF
Showing out of
Show more

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
2004
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Few (1-10%)
% of substance use disorder facilities offering hepatitis treatment
Few (1-10%)

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
2.58 (2.07 - 3.22) 2019 Modelled IHME
2.58 (2.08 - 3.23) 2018 Modelled IHME
2.58 (2.07 - 3.22) 2017 Modelled IHME
2.56 (2.06 - 3.16) 2016 Modelled IHME
2.54 (2.03 - 3.14) 2015 Modelled IHME
2.52 (2.02 - 3.11) 2014 Modelled IHME
2.5 (2.01 - 3.08) 2013 Modelled IHME
2.47 (2 - 3.06) 2012 Modelled IHME
2.46 (1.99 - 3.04) 2011 Modelled IHME
2.45 (1.98 - 3.04) 2010 Modelled IHME
2.46 (1.99 - 3.05) 2009 Modelled IHME
2.49 (2 - 3.08) 2008 Modelled IHME
2.53 (2.03 - 3.12) 2007 Modelled IHME
2.57 (2.07 - 3.17) 2006 Modelled IHME
2.61 (2.09 - 3.23) 2005 Modelled IHME
2.65 (2.12 - 3.28) 2004 Modelled IHME
2.68 (2.15 - 3.31) 2003 Modelled IHME
2.72 (2.18 - 3.35) 2002 Modelled IHME
2.76 (2.21 - 3.39) 2001 Modelled IHME
2.8 (2.24 - 3.44) 2000 Modelled IHME
2.84 (2.27 - 3.50) 1999 Modelled IHME
2.87 (2.31 - 3.55) 1998 Modelled IHME
2.91 (2.34 - 3.59) 1997 Modelled IHME
2.94 (2.36 - 3.67) 1996 Modelled IHME
2.97 (2.37 - 3.71) 1995 Modelled IHME
3 (2.40 - 3.75) 1994 Modelled IHME
3.02 (2.41 - 3.77) 1993 Modelled IHME
3.04 (2.43 - 3.79) 1992 Modelled IHME
3.06 (2.44 - 3.83) 1991 Modelled IHME
3.08 (2.44 - 3.84) 1990 Modelled IHME
Showing out of
Show more

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
24 (17 - 32) 2019 Modelled IHME
24 (17 - 31) 2018 Modelled IHME
24 (17 - 32) 2017 Modelled IHME
24 (17 - 31) 2016 Modelled IHME
24 (17 - 31) 2015 Modelled IHME
24 (17 - 31) 2014 Modelled IHME
24 (17 - 31) 2013 Modelled IHME
24 (17 - 31) 2012 Modelled IHME
24 (17 - 31) 2011 Modelled IHME
24 (17 - 31) 2010 Modelled IHME
24 (17 - 31) 2009 Modelled IHME
24 (17 - 31) 2008 Modelled IHME
24 (17 - 31) 2007 Modelled IHME
24 (17 - 32) 2006 Modelled IHME
24 (17 - 32) 2005 Modelled IHME
24 (17 - 32) 2004 Modelled IHME
24 (17 - 32) 2003 Modelled IHME
24 (17 - 32) 2002 Modelled IHME
24 (17 - 32) 2001 Modelled IHME
24 (17 - 33) 2000 Modelled IHME
24 (17 - 33) 1999 Modelled IHME
25 (17 - 33) 1998 Modelled IHME
25 (17 - 33) 1997 Modelled IHME
25 (17 - 33) 1996 Modelled IHME
25 (17 - 33) 1995 Modelled IHME
25 (17 - 33) 1994 Modelled IHME
25 (17 - 33) 1993 Modelled IHME
25 (17 - 33) 1992 Modelled IHME
25 (17 - 33) 1991 Modelled IHME
25 (17 - 33) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
2004
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Few (1-10%)
% of substance use disorder facilities offering hepatitis treatment
Few (1-10%)

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
8.66 (%)
2019
(7.32 - 10(%))
IHME
HCV (RNA/cAg+)
2.58 (%)
2019
(2.07 - 3.22(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
519
2019
(361 - 719)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
431
2019
(290 - 601)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
1.70 (%)
2012, survey/surveillance
WHO WPRO, Woodring J et al, 2017

Prevalence PWID

No data available

Birth dose vaccination coverage (national)

Survey/surveillance

HBV
55 (%)
2018
WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines